Welcome to our dedicated page for Nkarta news (Ticker: NKTX), a resource for investors and traders seeking the latest updates and insights on Nkarta stock.
Nkarta, Inc. reports developments as a clinical-stage biotechnology company developing allogeneic, off-the-shelf engineered natural killer (NK) cell therapies for autoimmune diseases. Company updates center on NKX019, an investigational CAR-NK cell therapy for B cell-mediated autoimmune diseases, and on the Ntrust-1 and Ntrust-2 clinical studies.
Recurring news themes include FDA protocol discussions, outpatient dosing plans, dose-escalation updates, B-cell depletion data, preclinical and clinical presentations, quarterly financial results, cash runway commentary, workforce and operating updates, and participation in healthcare and investor conferences.
Nkarta, Inc. (Nasdaq: NKTX) has announced its participation in several upcoming investor conferences, highlighting its focus on advancing NK cell therapies for cancer treatment. The events include the SVB Leerink 10th Annual Global Healthcare Conference on February 26, 2021, featuring a fireside chat at 1:40 p.m. ET, and the Cowen 41st Annual Health Care Conference on March 3-4, 2021, with no presentation scheduled. Additionally, Nkarta will present at the Barclays Global Healthcare Conference on March 11, 2021, at 10:20 a.m. ET. Live webcasts of these presentations will be available on their website.
Nkarta, Inc. has announced the dosing of the first patient in its Phase 1 clinical trial of NKX101, targeting acute myeloid leukemia and myelodysplastic syndromes. The company ended Q3 2020 with $330.2 million in cash, sufficient to fund operations through at least mid-2023. Nkarta plans to file an IND application for NKX019 in Q1 2021, focusing on B-cell malignancies. The Q3 financials revealed a net loss of $13.7 million, or $0.44 per share, alongside R&D expenses of $9.8 million and G&A expenses of $3.9 million.
Nkarta (Nasdaq: NKTX) has initiated its first-in-human Phase 1 clinical trial of NKX101 for treating relapsed/refractory acute myeloid leukemia (AML) or higher-risk myelodysplastic syndromes (MDS). This multi-center trial aims to evaluate safety and preliminary anti-tumor activity. NKX101 is engineered to enhance natural killer (NK) cell response by targeting NKG2D, improving cytotoxic activity significantly in preclinical models. The trial addresses a critical need for effective treatments in AML patients, who have limited options and poor outcomes.
Nkarta, Inc. (Nasdaq: NKTX) has provided a preclinical update on NKX019, an investigational allogeneic cancer immunotherapy focused on treating B cell malignancies. The findings, presented at the SITC 35th Annual Meeting, indicate that NKX019 showed strong anti-tumor activity against CD19-expressing cancer models, outperforming non-engineered NK cells and demonstrating advantages over CAR T cells. Notably, NKX019 displayed reduced cytokine release syndrome risk, suggesting a favorable safety profile. Nkarta plans to file an IND application for NKX019 in Q1 2021 and initiate a Phase 1 trial for advanced B cell malignancies.
Nkarta, a clinical-stage biopharmaceutical company focused on developing engineered natural killer (NK) cell therapies for cancer, has announced its participation in several upcoming investor conferences.
The events include:
- Cowen 2020 IO Next Summit on November 13, 2020, at 11:45 a.m. ET
- Stifel 2020 Virtual Healthcare Conference on November 17, 2020, at 2:00 p.m. ET
- Evercore ISI 3rd Annual HealthCONx Conference on December 1, 2020, at 9:40 a.m. ET
Audio webcasts will be available on Nkarta's website, with replays archived for about four weeks.
Nadir Mahmood, Ph.D. has been appointed as Chief Financial and Business Officer of Nkarta, Inc. (NASDAQ: NKTX), succeeding Matthew Plunkett, who stepped down to pursue other opportunities. Mahmood has been with Nkarta since 2018, contributing significantly to the company's strategy and operations. Alicia J. Hager, J.D., Ph.D. will join as Chief Legal Officer. Both leaders are expected to enhance Nkarta’s growth in developing engineered NK cell therapies for cancer.
Nkarta, Inc. (Nasdaq: NKTX) will participate in the Cantor Virtual Global Healthcare Conference on September 15, 2020, with a fireside chat presentation scheduled for 2:00 p.m. ET. The event will feature a live audio webcast available on Nkarta's website, with a replay archived for approximately four weeks.
Nkarta is focused on developing engineered natural killer (NK) cell therapies for cancer, utilizing a proprietary platform for efficient manufacturing and cell engineering aimed at enhancing tumor targeting and persistence.
Nkarta, Inc. (Nasdaq: NKTX) reported its Q2 2020 financial results, highlighting significant progress despite COVID-19 challenges. The company completed an IPO on July 14, 2020, raising $289.8 million and has cash and equivalents of $341.8 million as of June 30, 2020, sufficient to fund operations into late 2023.
NKX101 is set to enter Phase 1 trials in Q4 2020, with plans to file for NKX019 in Q1 2021. R&D expenses were $7.9 million, with a net loss of $51.1 million for the quarter. Financial guidance estimates cash reserves will range between $300 million and $310 million by year-end.
Nkarta, Inc. (Nasdaq: NKTX) has priced its initial public offering at $18.00 per share, offering 14,000,000 shares and expecting gross proceeds of approximately $252.0 million. The shares began trading on the Nasdaq Global Select Market on July 10, 2020, with the offering anticipated to close on July 14, 2020. A 30-day option is available for underwriters to purchase an additional 2,100,000 shares at the offering price. The offering is managed by Cowen, Evercore ISI, Stifel, and Mizuho Securities.